Cover Image

Drug Pricing of Domestic Anti-PD-L1 Antibody Adebrelimab: Cost-Effectiveness Analysis of the First-Line ES-SCLC Treatment in China

Dongchu Zhou,1 Xinrui Dong,1 Zhen Zhou,2 Qiao Liu1 1Department of Pharmacy, The Second Xiangya Hospital of Central South University, Changsha, People's Republic of China; 2School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, AustraliaCorrespondence: Qiao Liu, Depa...

Full description

Saved in:

Bibliographic Details
Main Authors:	Zhou D (Author), Dong X (Author), Zhou Z (Author), Liu Q (Author)
Format:	Book
Published:	Dove Medical Press, 2023-11-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Cost-effectiveness analysis of adebrelimab combined with chemotherapy for extensive-stage small cell lung cancer
by: Maojin You, et al.
Published: (2022)

Cost-Effectiveness of Domestic PD-1 Inhibitor Camrelizumab Combined With Chemotherapy in the First-Line Treatment of Advanced Nonsquamous Non-Small-Cell Lung Cancer in China
by: Liu Qiao, et al.
Published: (2021)

Adebrelimab plus chemotherapy vs. chemotherapy for treatment of extensive-stage small-cell lung cancer from the US and Chinese healthcare sector perspectives: a cost-effectiveness analysis to inform drug pricing
by: Yena Gan, et al.
Published: (2023)

Organ specific responses to first-line lenvatinib plus anti-PD-1 antibodies in patients with unresectable hepatocellular carcinoma: a retrospective analysis
by: Cheng Huang, et al.
Published: (2021)

Anti-PD-1/L1 antibody plus anti-VEGF antibody vs. plus VEGFR-targeted TKI as first-line therapy for unresectable hepatocellular carcinoma: a network meta-analysis
by: Yiwen Zhou, et al.
Published: (2024)

Integrated high-throughput analysis identifies super enhancers associated with chemoresistance in SCLC
by: Jiarong Bao, et al.
Published: (2019)

Population pharmacokinetics of adebrelimab - Support of alternative flat dose regimen in extensive‐stage small‐cell lung cancer
by: Peng Chen, et al.
Published: (2024)

The Multi-Omics Analysis of Key Genes Regulating EGFR-TKI Resistance, Immune Infiltration, SCLC Transformation in EGFR-Mutant NSCLC
by: Wang Z, et al.
Published: (2022)

First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis
by: Qiao Liu, et al.
Published: (2021)

The study of price situation on the domestic antiplatelet market
by: Ye. А. Redkina, et al.
Published: (2017)

Combination of chemotherapy and immune checkpoint therapy by the immunoconjugates-based nanocomplexes synergistically improves therapeutic efficacy in SCLC
by: Zhang Tao, et al.
Published: (2022)

Cost-effectiveness analysis of PD-1 inhibitors combined with chemotherapy as first-line therapy for advanced esophageal squamous-cell carcinoma in China
by: Shixian Liu, et al.
Published: (2023)

A Case of Metastatic Uterine Tumor Originating from Small-Cell Lung Cancer (SCLC) Mimicking Uterine Sarcoma
by: Mariko Fujima, et al.
Published: (2021)

The combination of anti-KIR monoclonal antibodies with anti-PD-1/PD-L1 monoclonal antibodies could be a critical breakthrough in overcoming tumor immune escape in NSCLC
by: He YY, et al.
Published: (2018)

Cost-Effectiveness Analysis of Tislelizumab Plus Chemotherapy as First-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma in China
by: Zhou C, et al.
Published: (2023)

Price-Transparency and Cost Accounting
by: Peter Hilsenrath PhD, et al.
Published: (2015)

The cost of sickness and the price of health
by: C.-E.A Winslow

Immune Checkpoint Inhibitors Plus an Anti-VEGF Antibody as the First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Network Meta-Analysis and Cost-Effectiveness Analysis
by: Lu Li, et al.
Published: (2022)

Identifying optimal PD-1/PD-L1 inhibitors in first-line treatment of patients with advanced squamous non-small cell lung cancer in China: Updated systematic review and network meta-analysis
by: Mingye Zhao, et al.
Published: (2022)

Advances in the structural characterization of complexes of therapeutic antibodies with PD-1 or PD-L1
by: Mengzhen Jiang, et al.
Published: (2023)

Quantification of Pharmacokinetic Profiles of PD-1/PD-L1 Antibodies by Validated ELISAs
by: Sara Zalba, et al.
Published: (2020)

The Humanistic Burden of Small Cell Lung Cancer (SCLC): A Systematic Review of Health-Related Quality of Life (HRQoL) Literature
by: Bryan M. Bennett, et al.
Published: (2017)

The Cost Effectiveness of Donafenib Compared With Sorafenib for the First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma in China
by: Rui Meng, et al.
Published: (2022)

Research Status and Outlook of PD-1/PD-L1 Inhibitors for Cancer Therapy
by: Ai L, et al.
Published: (2020)

Cost-Effectiveness Analysis of Sintilimab Combined with Chemotherapy Versus Chemotherapy Alone as the First-Line Treatment for Advanced Esophageal Cancer
by: Zhuo-Miao Ye, et al.
Published: (2022)

Cost-Effectiveness of First-Line Atezolizumab versus Chemotherapy in Non-Small-Cell Lung Cancer Patients Ineligible for Platinum-Containing Regimens
by: Li LF, et al.
Published: (2024)

Cost-effectiveness of nivolumab plus ipilimumab as first-line treatment for American patients with unresectable malignant pleural mesothelioma
by: Zhuo-miao Ye, et al.
Published: (2022)

Cost-Effectiveness Analysis of Pembrolizumab Plus Chemotherapy vs. Chemotherapy Alone as First-Line Treatment in Patients With Esophageal Squamous Cell Carcinoma and PD-L1 CPS of 10 or More
by: Zhiwei Zheng, et al.
Published: (2022)

Total coumarins of Pileostegia tomentella induces cell death in SCLC by reprogramming metabolic patterns, possibly through attenuating β-catenin/AMPK/SIRT1
by: Ying Liu, et al.
Published: (2023)

COST-ORIENTED PRICES TO RENT SPORTS FACILITIES
by: Dragan Vukasović, et al.
Published: (2012)

Cost-utility analysis of lurasidone for the first-line treatment of schizophrenia in China
by: Jia Liu, et al.
Published: (2022)

Product review: avelumab, an anti-PD-L1 antibody
by: Julie M. Collins, et al.
Published: (2019)

Product review on the Anti-PD-L1 antibody atezolizumab
by: Neil J. Shah, et al.
Published: (2018)

Comparison of the profiles of first-line PD-1/PD-L1 inhibitors for advanced NSCLC lacking driver gene mutations: a systematic review and Bayesian network meta-analysis
by: Fu Wenfan, et al.
Published: (2023)

Optimizing first-line TKI treatment efficacy in PD-L1-positive EGFR-mutated NSCLC: the impact of antiangiogenic agents
by: Xuanhong Jin, et al.
Published: (2024)

Association Analysis of Free Thyroid Hormones, Subclinical Hypothyroidism, and Thyroid Peroxidase Antibody in the First Trimester with Gestational Diabetes Mellitus
by: Yi Zhou, et al.
Published: (2023)

The usage and costs of national drug price-negotiated anticancer medicines in a first-tier city in Northeast China: a study based on health insurance data
by: Bao-Xin Li, et al.
Published: (2024)

Corrigendum: Cost-utility analysis of lurasidone for the first-line treatment of schizophrenia in China
by: Jia Liu, et al.
Published: (2022)

Cost-effectiveness of early initiation of first-line combination antiretroviral therapy in Uganda
by: Sempa Joseph, et al.
Published: (2012)

Cost-effectiveness analysis of sintilimab plus bevacizumab biosimilar compared with lenvatinib as the first-line treatment of unresectable or metastatic hepatocellular carcinoma
by: Ting Zhou, et al.
Published: (2022)